Your AI-Trained Oncology Knowledge Connection!

Mark Yarchoan, MD

home / authors / mark-yarchoan-md

Articles

Case 4: Later Lines of Therapy for Patients With Recurrent HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 29th 2022

Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.

Case 3: Novel Frontline Combination Strategies for Unresectable HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 29th 2022

Comprehensive insight on several clinical trials analyzing frontline combination therapies for patients with unresectable hepatocellular carcinoma.

Case 3: A 63-Year-Old With Unresectable HCC Eligible for IO Therapy

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 29th 2022

In the setting of unresectable hepatocellular carcinoma, experts consider the role of frontline atezolizumab + bevacizumab given data from IMbrave150.

Case 2: Treating Child-Pugh B Metastatic Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 22nd 2022

A brief review of treatment options for patients with Child-Pugh B grade metastatic hepatocellular carcinoma.

Case 2: Adverse Event Management and Dosing of Frontline TKIs

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 22nd 2022

Panelists consider the adverse event profile of frontline TKI therapy in patients with metastatic HCC and review options for dosing and dose reduction.

Case 2: PFS Subgroup Data From the REFLECT Trial in Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 15th 2022

Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.

Case 2: Data Supporting Frontline TKI Therapy in Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 15th 2022

Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.

Case 2: Selecting Frontline Therapy for Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 8th 2022

Focused discussion on the frontline treatment options available for patients diagnosed with metastatic hepatocellular carcinoma.

Case 2: Role of Biopsy and Imaging in Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 8th 2022

Panelists debate the role of imaging in conjunction with or in place of biopsy in the setting of metastatic hepatocellular carcinoma.

Case 2: A 75-Year-Old With Metastatic HCC

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 1st 2022

Shifting to a second patient case of metastatic hepatocellular carcinoma, experts consider best diagnostic practices and the initiation of therapy.

Case 1: Systemic Therapy in Combination With or Following TACE/TARE

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

July 1st 2022

A brief discussion on the role of systemic therapies in combination with or following TACE/TARE in unresectable hepatocellular carcinoma.

Case 1: Role of TARE in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD;Riad Salem, MD, MBA;Amit Singal, MD;Mark Yarchoan, MD

June 24th 2022

Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.

Case 1: A 60-Year-Old With Unresectable Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, MD;Amit Singal, MD;Mark Yarchoan, MD;Riad Salem, MD, MBA

June 24th 2022

Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.

Yarchoan Compares Lenvatinib and Sorafenib for Child Pugh B and C Hepatocellular Carcinoma

Mark Yarchoan, MD

September 13th 2021

During a Targeted Oncology Case-Based Roundtable event, Mark Yarchoan, MD, moderates a discussion about a 77-year-old woman with Child Pugh B and C hepatocellular carcinoma.